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A B S T R A C T
In birds, exposure to exogenous testosterone during embryonic development can suppress measures of immune
function; however, it is unclear whether these effects are due to direct or indirect action via aromatization.
Estradiol (E2) is synthesized from testosterone by the enzyme aromatase, and this conversion is a necessary step
in many signaling pathways that are ostensibly testosterone-dependent. Many lines of evidence in mammals
indicate that E2 can affect immune function. We tested the hypothesis that some of the immunomodulatory
effects observed in response to in ovo testosterone exposure in birds are mediated by conversion to E2 by ar-
omatase, by using fadrozole to inhibit aromatization of endogenous testosterone during a crucial period of
embryonic immune system development in domestic chickens (Gallus gallus). We then measured total IgY an-
tibody count, response to PHA challenge, mass of thymus and bursa of Fabricius, and plasma testosterone post-
hatch on days 3 and 18. Because testosterone has a reputation for immunosuppression, we predicted that if
modulation of an immune measure by testosterone is dependent on aromatization, then inhibition of estrogen
production by fadrozole treatment would lead to elevated measures of that parameter. Conversely, if testos-
terone inhibits an immune measure directly, then fadrozole treatment would likely not alter that parameter.
Fadrozole treatment reduced circulating E2 in female embryos, but had no effect on males or on testosterone in
either sex. Fadrozole-treated chicks had decreased day 3 plasma IgY antibody titers and a strong trend towards
increased day 18 thymic mass. Furthermore, fadrozole treatment generated a positive relationship between
testosterone and thymic mass in males, and tended to increase day 18 IgY levels for a given bursal mass in
females. There was no effect on PHA response, bursal mass, or plasma testosterone at either age post-hatch. The
alteration of several indicators of immune function in fadrozole-treated chicks implicates aromatization as a
relevant pathway through which developmental exposure to testosterone can affect immunity in birds.
1. Introduction
The vertebrate immune system is responsible for defending the body
from a variety of external threats and must be tightly regulated to op-
timize protection from disease. Investment in immune defenses begins
as early as oocyte formation, when the mother deposits maternal an-
tibodies, which will form the basis of embryonic immunity, into the egg
(Ulmer-Franco, 2012). Of the multiple environmental and genetic fac-
tors that influence immune function, differential hormonal exposure is
a prominent source of immunological variability (Olsen and Kovacs,
1996). While variation in hormone levels can transiently affect immune
function in adults, hormone-mediated actions during development have
the potential to permanently alter the trajectory of an individual’s im-
mune phenotype (Navara and Mendonca, 2008).
Of the hormones thought to influence immune development, tes-
tosterone has a reputation as a potent immunomodulator, and has long
been described as a general inhibitor of immune activity (Roberts et al.,
2004; Folstad and Karter, 1992). Testosterone exposure can suppress
functionality of both B lymphocytes (antibody-producing cells) and T
lymphocytes (regulators of cell-mediated immunity) in vitro
(Cunningham and Gilkeson, 2011). In addition, a variety of vertebrate
taxa exhibit decreased immune activity when treated with androgens.
For instance, in adult mammals, androgen exposure causes apoptosis in
cells of the thymus (the site of T cell maturation), as well as in circu-
lating T cells and macrophages (Olsen and Kovacs, 1996). Studies of
testosterone exposure during early development have reported similar
effects. Experiments exploring potential trade-offs generated by varia-
tion in yolk testosterone levels have injected testosterone into eggs and
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found an array of effects on immune function, ranging from decreased
post-hatch T cell concentrations and suppressed T cell-mediated re-
sponses to phytohemagglutinin (PHA), a general irritant and T cell
mitogen (Andersson et al., 2004; Groothuis and Ros, 2005; Navara
et al., 2005; Muller et al., 2005), to mixed effects where some immune
measures were attenuated (pro-inflammatory cytokines) while others
were increased (non-specific antibody response to LPS) (Kankova et al.,
2018). In chickens, individuals from eggs treated with high doses of
testosterone propionate show depressed antibody levels, as well as re-
duced weight of the bursa of Fabricius, an exclusively avian organ re-
sponsible for B-cell development and acquired immunity (Glick, 1961;
Norton and Wira, 1977; Hirota et al., 1976). Thus, in birds, early ad-
ministration of testosterone can inhibit several types of immune cells
and immune cell generation, and these effects can persist after
hatching.
1.1. Aromatase and Estradiol
Despite evidence for testosterone-induced immunosuppression, our
mechanistic understanding of testosterone’s complex role in immunity
remains incomplete. Cytochrome P450 aromatase is an enzyme that
converts androgens to estrogens, including converting androstenedione
to estrone and testosterone to 17β-estradiol- (E2) – all E2 must be de-
rived either from testosterone or from androstenedione via estrone as
an intermediate, with both pathways requiring aromatization (Simpson
et al., 2002). In addition, local conversion of testosterone to E2 by ar-
omatase is a key step in many signaling pathways purported to be
testosterone-dependent. For instance, copulatory behavior in male quail
requires aromatization of testosterone (Watson and Adkins-Regan,
1989) while in song sparrows, display of male territorial aggression
during the non-breeding season are similarly dependent on the activity
of aromatase (Soma et al., 2000). Experiments such as these suggest
that many of the effects of testosterone are not regulated via direct
action of androgen on androgen receptors but instead are mediated by
aromatization to E2; thus aromatization may also play a crucial role in
aspects of putatively testosterone-dependent regulation of immunity.
The role of aromatization in immunomodulation has been studied
extensively within the biomedical field (Subramanian et al., 2008;
Niravath, 2013; Tanriverdi et al., 2003) and the prospect of im-
munosuppression by E2is frequently discussed in the context of xe-
noestrogens and other endocrine disruptors (Chalubinski and Kowalski,
2006; Razia et al., 2006; Markman et al., 2008). However, this pathway
is often overlooked in other contexts, despite the long-standing
knowledge that maternal testosterone can induce immunosuppression
and acknowledgment of aromatization as a potential fate of testos-
terone (Owen-Ashley et al., 2004). Estrogens affect many components
of the immune system, upregulating some and down-regulating others
(Klein and Flanagan, 2016). Like testosterone, E2 inhibits the T cell
mediated response to PHA in vitro and causes dose-dependent thymic
atrophy in mice (Ablin et al., 1974; Wyle and Kent, 1977; Rijhsinghani
et al., 1996; Okasha et al., 2001; Staples et al., 1999; Tai et al., 2008).
Similarly, E2 downregulates B cell lymphopoiesis in humans (Hill et al.,
2011). The few existing studies in birds are largely restricted to adult or
juveniles, and have found that E2 tends to depress cell-mediated im-
munity, although reported effects on humoral immunity have been
inconsistent (Owen-Ashley et al., 2004). Similarly, E2 administration to
chicken eggs on day 14 of incubation caused a suppressed antibody
response to killed Brucella abortus 2–4 weeks after hatching, as well as a
bursal weight reduction (Kondo et al., 2004). Thus, in birds there are
similarities between the immunomodulatory effects of testosterone and
E2 that may implicate aromatization as a mechanism through which
developmental exposure to testosterone acts on the immune system.
However, given the immune enhancing effects of E2 on multiple
immune traits in mammals, immunomodulatory effects of sex hormones
in birds are likely to be trait-specific as well as variable across taxa and
window of exposure (e.g. embryonic development vs adulthood) (Fish,
2008; Giefing-Kröll et al., 2015; Ahmed et al., 2010). Studies with non-
aromatizable androgens such as DHT (dihydrotestosterone) or weakly-
aromatizable androgens such as 19-nortestosterone (NorT) have pro-
vided support for the proposition that the role of aromatization in avian
immunity is trait-specific. For instance, treatment of immature broiler
chicks with E2 or testosterone resulted in a decline in leukocytes,
lymphocytes, and bursal weight, while administration of DHT did not
(Al-Afaleq and Homeida, 1998). Similarly, while implantation of ca-
ponized chickens with either testosterone or NorT implants both caused
bursal atrophy, testosterone resulted in a reduction of spleen weight as
well as PHA response, while NorT administration increased these im-
mune metrics (Chen et al., 2010). While the importance of aromatiza-
tion in immune regulation has been acknowledged in mammals
(Martin, 2000) and in avian adults and juveniles, to our knowledge no
prior studies have explored the role of aromatization during embryonic
immune system development in birds, despite frequent study of the
effects of exogenous testosterone on immune function in developing
birds.
The purpose of our study was to determine whether conversion of
endogenous androgens to estrogens is involved in regulating develop-
ment of immune function in birds. We tested this by manipulating ar-
omatase activity during development by exposing chicken embryos to
an aromatase inhibitor, fadrozole, during a critical window for immune
tissue development. For each immune trait measured, we consider three
potential hypotheses. The first hypothesis asserts that the reduction in
immune function documented in birds in response to embryonic tes-
tosterone administration is due (at least in part) to aromatization of
androgens to estrogens. According to this hypothesis, aromatase in-
hibition in ovo would result in elevated immune activity relative to
controls. The second hypothesis asserts that aromatization is not in-
volved in regulating immune activity of developing birds. Therefore,
according to this hypothesis exposure to an aromatase inhibitor a)
would not change immune activity, or b) may actually decrease im-
mune activity relative to controls if testosterone is immunosuppressive
and inhibition of aromatase causes a buildup of testosterone due to lack
of negative feedback in the hypothalamus. The third hypothesis states
that estrogens enhance immunity rather than suppressing it, and thus
aromatization induces a regulatory transition to greater immune ac-
tivity. Under this hypothesis, aromatase inhibition would lead to re-
duced immunity (similar to the second hypothesis) but in this case due
to the absence of estrogen receptor (ER) stimulation rather than an
increase in androgen receptor (AR) signaling. Notably, the role of ar-
omatization in immunity need not be unidirectional; the influence of
AR and ER signaling may be trait-specific, and thus each metric of
immune physiology or function should be considered separately.
2. Methods
2.1. Immune traits
We measured several traits representing different branches of the
immune system. To measure acquired immunity, plasma IgY antibody
levels were assayed at three points during development. IgY is the
major immunoglobulin in birds, and is functionally similar to mam-
malian IgG antibody. Maternal IgY is deposited in egg yolk and is se-
lectively transferred to the embryo via an IgY receptor (FcRY) em-
bedded in the yolk cell membrane (Tesar et al., 2008). This maternally
derived IgY acts as the basis of acquired immunity for the developing
chick until it is able to produce its own at approximately day 6 post-
hatch (Hamal et al., 2006). Because all IgY present before post-hatch
day 6 is maternally derived, IgY titers before this point in development
reflect uptake or retention of maternal antibodies. After day 6, IgY le-
vels reflect a mixture of maternally derived and endogenous im-
munoglobulin. By day 14, maternal IgY levels are undetectable and all
IgY is synthesized endogenously (Hamal et al., 2006). Previously, E2
administration to hens has been shown to increase deposition of
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maternal IgY into egg yolk (Barua et al., 2000). The mass of the bursa of
Fabricius (hereafter “bursa”) was also recorded as a potential indicator
of B lymphocyte generation, as bursal mass and antibody production
are correlated (Glick, 1956; Sadler and Glick, 1962). Previous studies
have produced mixed results with respect to hormonal influence on
bursal mass: Al-Afaleq et al., documented a reduction in bursal weight
due to testosterone and E2 but not DHT (Al-Afaleq and Homeida, 1998),
while Quinn et al observed an increase in the same metric due to de-
velopmental E2 exposure (Quinn et al., 2009).
To assess T cell mediated immunity, swelling in response to PHA
injection was measured (Hasselquist and Nilsson, 2012). A study by
Chen et al. previously demonstrated that the PHA response was in-
creased by non-aromatizable androgens but reduced by testosterone
(Chen et al., 2010). Additionally, thymic mass was recorded as an im-
mune metric as both testosterone and E2 have been shown to induce
thymic atrophy in mammals, with aromatase inhibition preventing this
process (Staples et al., 1999; Greenstein et al., 1992).
All procedures were approved by Bucknell University’s IACUC.
2.2. Eggs, fadrozole injection and validation
All eggs were fertilized, unincubated, White Leghorn domestic
chicken eggs (Gallus gallus) from Moyer’s Chicks in Quakertown, PA.
They were incubated at 37.5 °C and 50% humidity in an OVA-Easy
Advance incubator (Brinsea, Titusville, FL, USA) with a 90-minute turn
cycle. We used two sets of eggs: One with which to validate the effec-
tiveness of fadrozole in embryonic chickens (embryos were euthanized
at day 15 of incubation for blood collection), and one in which chicks
were reared to day 14 post-hatch. For both, eggs were sorted into
control and fadrozole groups to balance the distribution of mass, and on
day 13 of incubation 0.1 mg of fadrozole hydrocholoride (Sigma-
Aldrich, St. Louis, MO, USA; F3806) dissolved in 0.1 mL of 0.9% NaCl
saline solution or saline only was injected in the air sac using a ½ inch,
27 g needle as previously described (Abinawanto and Saito, 1997; Yang
et al., 2008).
Fadrozole is a non-steroidal aromatase inhibitor that reduces ar-
omatase activity to near undetectable levels, and thus prevents any
endogenous androgens from being converted into estrogens (Yue and
Brodie, 1997). The dose of fadrozole was selected because it eliminates
aromatase activity without reducing hatchability in chickens (Yang
et al., 2008). To our knowledge, there are no studies that measure the
elimination time of a single dose of fadrozole from an egg. However,
administration of 0.1 mg of fadrozole (the same dose used in this study)
to White Leghorn chicken eggs at day 5 of incubation induced full sex
reversal in developing females, demonstrating that a single dose during
development can have lasting effects on physiology (Abinawanto and
Saito, 1997). The timing of fadrozole injection was selected based on
studies showing that lymphoid stem cells have fully colonized the
bursal primordium in chickens by day 14 of incubation, and that es-
trogen receptor expression in embryonic bursa and endogenously-de-
rived plasma testosterone levels in both sexes are at a maximum at this
age (Houssaint et al., 1976; Kondo et al., 2004; Woods et al., 1975).
These studies suggest that this window of time is critical for estrogen
signaling in developing immune tissues, and thus, if estrogens affect
immune system development, fadrozole administration is likely to have
pronounced effects during this period.
For the fadrozole validation, 97 eggs were distributed between
treatments and injected on day 13 of incubation; egg mass did not differ
between treatments (control: 56.96 ± 4.32 g, fadrozole:
56.71 ± 3.66 g). The 80 surviving embryos were bled and euthanized
on day 15 of incubation. The egg was broken open exposing the embryo
and its blood vessels, and a needle was used to puncture a major visible
blood vessel on the yolk sac. Blood was collected with capillary tubes,
separated by centrifugation, and placed in the −20 °C freezer. Genetic
sex of each of the embryos was determined as described in section 2.6.
Because plasma volumes were limited (20–200 µL), the samples were
allocated to either testosterone or E2 groups, distributed evenly by sex
and treatment.
2.3. Chicks
To determine the influence of transient in ovo fadrozole exposure on
post-hatch immune measures, a separate batch of 80 fertilized, unin-
cubated White Leghorn domestic chicken (Gallus gallus) eggs were
sorted into control and fadrozole groups; egg mass did not differ be-
tween treatments (control: 44.9 ± 0.8 g; fadrozole: 45.3 ± 0.7 g). On
day 13 of embryonic development, the eggs were injected with either
control or fadrozole solutions in the same manner as described above.
On day 18 pre-hatch, eggs were transferred to a 1550 Hatcher (GQF,
Savannah, GA, USA) at 36.7 °C and 60% humidity with no rotation.
Chicks hatched on day 21 of incubation. Hatchlings were sexed based
on feather structure (chickens of this strain are feather-sexable), banded
in the wing web, weighed, and transferred to a brooder maintained at
35 °C. 71 (88.75%) chicks hatched over a period of 32 h. Chicks that
had not hatched by 24 h following the first round of hatching were
excluded from the experiment to minimize variability associated with
hatching date, leaving a total sample of 58 chicks (16 control female, 16
control male, 12 fadrozole female, 14 fadrozole male). Once all ex-
perimental chicks had hatched, they were redistributed such that sex
and treatment were balanced across three brooders. Chicks were given
food and water ad libitum and kept on a 12:12 L:D photoperiod. Chicks
were weighed every three days at 9 AM when the lights were turned on.
The temperature was reduced by 3 °C each week and maintained con-
stant once it reached 30 °C. All data were collected and samples ana-
lyzed by investigators blind to treatment.
2.4. PHA challenge
On day 3, day 13, and day 18 post-hatch, blood samples were drawn
from the alar vein, using ½ inch, 26 g needles and capillary tubes.
Samples were kept on ice and separated by centrifugation within an
hour of collection; plasma was removed and stored at −20 °C until use
in assays.
On day 14 post-hatch, a subset of chicks (36, distributed evenly
across sex and treatment) were injected in the wing web of the un-
banded wing with 0.1 mg of PHA (Sigma-Aldrich, St. Louis, MO, USA;
L8754) dissolved in 0.06 mL of phosphate buffered saline (PBS), or with
PBS alone, following web thickness measurement with a digital mi-
crometer according to established protocols (Martin et al., 2006). Three
measurements were taken and the average was used in calculations.
Immediately following initial wing web thickness measurements, a ½
inch, 27 g needle tip on a 100 μL disposable syringe was used to slowly
inject the PHA solution into the site of measurement. Nine chicks from
each sex and treatment group were injected. 24 h later (± 1 h), the site
of injection was measured again as described above. PHA injection did
not influence any of the other metrics that we measured.
2.5. Immune tissue
On day 18 post-hatch, following a final blood sample collection,
chicks were euthanized by decapitation. The bursa of Fabricius and
thymus were extracted and weighed, and diagonal tarsus length was
measured using a digital caliper (VWR, Radnor, PA, USA). Bursal mass
and thymic mass were corrected for body size by dividing by overall
body mass (as in Kondo et al., 2004).
2.6. Sex determination
Sex was confirmed both by visual inspection of gonads and by ge-
netic sexing (Abinawanto and Saito, 1997). Genetic sex was determined
with PCR and gel electrophoresis using AmplitaqGold PCR master mix
(Applied Biosystems, Waltham, MA, USA; L00192), primers AvianSex
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2550F (GTTACTGATTCGTCTACGAGA) and AvianSex2718R (ATTGAA
ATGATCCAGTGCTTG) (Fridolfsson and Ellegren, 1999), and 2.5%
high-resolution agarose gels, which show one band for males and two
for females. One fadrozole-treated chick demonstrated potential sex-
reversal: it was initially identified as male based on feathers and go-
nads, but showed two bands in both of two rounds of genetic sexing.
This chick was treated as female for subsequent analyses, though ex-
cluding this individual did not alter outcomes.
2.7. IgY content analysis
Plasma IgY content was determined using a Chicken IgG ELISA
Quantification Set (Bethyl, Montgomery, TX, USA; E30-104–25).
Dilutions of 1:40000 were consistently in the center of the standard
curve and thus samples were analyzed in duplicate at this dilution ratio.
Treatment groups were distributed equally across 5 plates with samples
from the same chick kept on the same plate. Inter-assay variation based
on an internal standard was 15.6%, while intra-assay variation for
duplicate samples was typically in the 0–5% range (µ = 2.7 ± 2.5%).
2.8. Plasma steroids
2.8.1. Embryos
Because of the high lipid content of embryonic plasma, steroids
were extracted from embryonic plasma samples with dichloromethane
following protocols described in (Moore et al., 2002), and recoveries
were calculated from tritiated corticosterone (2000 cpm/sample). Each
sample value was corrected for its individual recovery. Testosterone
and E2 were quantified using Expanded Range Salivary Testosterone
Enzyme Immunoassay kit (Salimetrics, State College, PA, USA 1-2312)
and High Sensitivity Salivary 17β E2 Enzyme Immunoassay kit (Sali-
metrics, State College, PA, USA 1-4702), both with detection limits of
1 pg/mL. Serial dilutions were used to confirm parallelism with the
standard curve for the extracted steroids. There was a negative re-
lationship between plasma volume and final concentration, which
suggests that samples from low plasma volumes had inflated final
concentrations. Therefore, samples with< 100 μL were excluded from
all further analyses, eliminating this relationship and resulting in final
sample sizes of 36 for both E2 and testosterone. Testosterone was
measured in duplicate but there was not sufficient sample to assay E2 in
duplicate. The average % CV for the testosterone assay was 6.05%.
2.8.2. Chicks
The same Salimetrics kit was used to quantify testosterone in chick
plasma on day 3 and day 18 post-hatch. Because this kit has been used
successfully to quantify plasma testosterone in several avian species,
and serial dilutions of unextracted chick plasma were parallel with the
standard curve (Washburn et al., 2007; Marteinson et al., 2011), we did
not run an extraction. Samples were run across 3 plates, and samples
from the same individual at both ages were run on the same plate to
reduce inter-assay variation. Inter-assay variation based on high and
low controls were 6.7% and 3.4% respectively, and intra-assay varia-
tion for duplicate samples was 5.2 ± 5.1%. Testosterone was not de-
tectable in some plasma samples; for these, we set values to 1 pg/mL,
the lower detection limit for the assay, but also ran the statistical
analyses without the undetectable samples included. We were unable to
detect plasma E2 with the small remaining quantities of plasma.
2.9. Statistical analyses
We validated the effect of fadrozole on circulating E2 and testos-
terone in embryos that were sampled at day 15 of incubation (details
above). We analyzed the E2 and testosterone data using generalized
linear models. All models included sex, treatment (fadrozole or con-
trol), and their interaction, to determine if the effect of treatment on
circulating hormone concentrations varied depending on the sex of the
embryo. We used post-hoc Tukey tests of least squares means to con-
trast hormone concentrations among groups.
We conducted all of our main analyses in R (version 3.0.2). For all of
our analyses, we selected the models that best fit the data using model
comparison with Akaike’s Information Criterion corrected for small
sample size (AICc) using the dredge command in the R package MuMIn
(Symonds and Moussalli, 2011). When more than one model was within
2 AICc of the top model, we report model-averaged effects across the
top models using the model.avg command, also in MuMIn (Posada and
Buckley, 2004; Burnham and Anderson, 2004). However, if only one
model was best fit (i.e., no other models within 2 AICc), we only report
results from that model. For all analyses, we initially ran linear mixed-
effects models (LMEs, using the command lmer in the package lme4) and
assessed the effect of inclusion of a random grouping effect of brooder
(i.e., the compartment in which hatchlings were housed – hatchlings
were housed in 3 different brooders) by comparing the AICc of the full
model containing or lacking this random effect. If the AICc was>2
lower when this random effect was included, we retained it in the full
model that was then used in model selection for fixed effects. For all
models analyzing response metrics that were estimated more than once
within individuals, we included individual identity as a random effect.
For models where a random effect was not retained (because in-
dividuals were only sampled once, and brooder did not improve model
fit), we used generalized linear models (GLMs) instead of LMEs. We
checked the fit of all top models by visually examining plotted re-
lationships between predicted values and model residuals, and fixed
effects and residuals, as well as by testing for normal distribution of
residuals.
To determine if the treatment influenced any of the response metrics
(production or uptake of IgY, bursal or thymic mass, post-hatch tes-
tosterone, or the PHA response) we conducted separate LMEs with the
full model containing treatment (control or fadrozole-treated), sex,
body mass, and age (3, 13, or 18 days old) as fixed effects where ap-
propriate. We log-transformed IgY and testosterone concentrations to
fit a normal distribution. We corrected bursal mass and thymic mass by
dividing by body mass, so we did not include body mass in these
models. We also included the interactions of treatment by age and
treatment by sex. If fadrozole treatment influenced any of the response
variables, the treatment main effect or treatment by age interaction
effect would be significant.
We also conducted an additional analysis to determine if treatment
with fadrozole influenced the efficiency of IgY production by the bursa.
We used an LME with log-transformed IgY measured at 18 days old as
the dependent variable. The full model included treatment, size-cor-
rected bursa (as described above), sex, and body mass, as well as the
interactions of bursa by treatment, bursa by sex, treatment by sex, and
treatment by sex by bursa as fixed effects. If treatment influenced the
production of IgY by the bursa, we would predict that the relationship
between bursa mass and IgY would differ for fadrozole-treated birds
(i.e., a significant bursa by treatment interaction effect).
Finally, to determine if treatment with fadrozole influenced the
relationship between testosterone and thymic mass, we conducted an
LME with size-corrected thymic mass as the dependent variable. The
full model included treatment, log-transformed testosterone (measured
at 18 days old), sex, and all possible 2-way interactions and the 3-way
interaction as fixed effects. If fadrozole treatment influences the effect
of testosterone on thymic mass, we would predict that the relationship
between testosterone and thymic mass would differ for fadrozole-
treated birds (i.e., a significant treatment by testosterone effect).
3. Results
3.1. Hatching & growth
All chicks included in the experiment hatched within 24 h of each
other. Hatching success did not differ between treatments (90% (36 out
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of 40 eggs) for control and 85% (34 out of 40 eggs) for fadrozole-treated
chicks; (χ2(1, N = 80) = 0.125, p = 0.723). Fadrozole treatment did
not affect hatch mass (F1,56 = 0.363, p = 0.549), body mass gain
(F1,56 = 0.209, p = 0.65), or day 18 tarsus length (F1,55 = 0.63,
p = 0.431).
3.2. Fadrozole activity validation
Testosterone data were normally distributed, so raw data were
analyzed. Fadrozole treatment did not affect circulating testosterone
concentrations, regardless of embryo sex (sex by treatment interaction:
F1,34 = 0.08, p = 0.78, main treatment effect: F1,34 < 0.001,
p = 0.99; Fig. 1A). Testosterone tended to be higher in female embryos
relative to males, regardless of treatment group (Tukey test, z = 1.84,
p = 0.067). E2 data were log-transformed prior to analysis to meet
assumptions of normality. On day 15 of incubation (2 days post-injec-
tion), the effect of treatment with fadrozole on E2 concentrations de-
pended on sex of the embryo (sex by treatment interaction:
F1,32 = 6.63, p = 0.015; Fig. 1B). Fadrozole-treated females had lower
circulating E2 than control females (Tukey test, z = 3.69, p = 0.0002),
but E2 did not differ among control and fadrozole-treated males (Tukey
test, z = -0.06, p = 0.95).
3.3. Plasma IgY concentrations
Inclusion of brooder as a random effect improved model fit
(σ2 = 0.002 ± 0.04; all random effects reported as estimated var-
iance ± standard deviation), so model comparison was conducted
with an LME including both brooder and individual identity
(σ2 = 0.004 ± 0.06) as random effects (because IgY was estimated in
the same individuals three times). The 6 best-fit models for explaining
variation in IgY concentrations retained age of the individual, treat-
ment, body mass, sex, and an interaction of treatment by age in various
combinations (Table 1). In model-averaged estimates, only age, treat-
ment, and the treatment by age interaction were related to IgY con-
centrations. Overall, IgY declined with age (β = -0.054, p < 0.001)
and was lower in fadrozole-treated birds versus controls (β = -0.071,
p = 0.018), but this difference diminished with age (β = 0.004,
p = 0.037; Fig. 2).
3.4. Bursal mass
Inclusion of brooder as a random effect did not improve model fit
(σ2 < 0.0001 ± 0.00), so a GLM without any random effect was used
for model selection. The best-fit model was the null model, but 3 other
models were similarly well fit to the data as the null (i.e., within 2
AICc). These models individually included fixed effects of phytohe-
magglutinin (PHA) status (whether or not the bird was injected with
PHA), treatment, or sex. However, in model averaging, none of the
effects of these factors were significant predictors of bursa mass (all
p > 0.3). Thus, treatment with fadrozole did not affect size-corrected
bursal mass.
3.5. Thymic mass
Inclusion of brooder as a random effect did improve model fit
(σ2 < 0.0001 ± 0.00), so model selection was conducted using an
LME with this random effect retained. The 3 best-fit models contained
sex, treatment, and their interaction (Table 2). Model averaged effects
reveal that, overall, males tended to have lower size-corrected thymic
mass (β =−0.001, p= 0.083), and that fadrozole-treated birds tended
to have higher size-corrected thymic mass (β = 0.001, p = 0.056;
Fig. 3). The interaction term was not significant.
3.6. Post-Hatch plasma testosterone concentration
Inclusion of brooder as a random effect did not improve model fit
(σ2 = 0.00 ± 0.00), so model selection was conducted using an LME
with only individual identity as a random effect (σ2 = 0.00 ± 0.00;
retained because testosterone was measured twice in each individual).
The 3 best fit models retained age, body mass, and sex; treatment was
Fig. 1. Plasma (A) testosterone and (B) E2
concentrations at day 15 of incubation
(2 days post-injection) for control and fa-
drozole-treated birds. For each boxplot, the
middle line represents the median, the
bottom and top hinges represent the 25th
and 75th percentiles, respectively, and the
whiskers extend to the furthest outliers still
within 1.5x the interquartile range from the
nearest hinge (25th or 75th percentile).
Table 1
Predictors of IgY concentrations estimated using model averaging for the 6 best-
fit models (all within 2 AICc of the top model).
Fixed effect Estimate SE z P
Age −0.054 0.004 12.44 <0.001
Treatment −0.071 0.030 2.37 0.018
Body mass 0.001 0.001 1.42 0.156
Sex −0.018 0.022 0.81 0.417
Treatment by age 0.004 0.002 2.09 0.037
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not retained in any of the top models. Model-averaged estimates from
the best-fit models indicate that testosterone was higher in males than
females (β = 0.856, p < 0.001) and declined with age (β = -0. 151,
p = 0.045). The effect of body mass was not significant (β = 0.007,
p = 0.202). Results are similar if birds without detectable testosterone
concentrations are excluded from the analyses; however, the decline
with age is dampened and no longer significant (β = -0.026,
p = 0.186). Thus, treatment with fadrozole did not affect circulating
testosterone concentrations in 3- or 18-day old birds (Fig. 4).
3.7. IgY-Bursa relationship
The inclusion of brooder as a random effect (σ2 = 0.002 ± 0.04)
did not improve model fit, so model selection was conducted with a
GLM. The 3 best-fit models retained treatment, size-corrected bursal
mass, sex, a sex by bursal mass interaction, a treatment by bursa in-
teraction, and a sex by treatment interaction effect (Table 3). Model
averaging revealed both a sex-dependent (β = -104.5, p < 0.001) and
a treatment-dependent relationship between bursal mass and IgY
(β = 67.14, p = 0.027). Within females, fadrozole exposure caused the
positive relationship between bursal mass and day 18 IgY to increase in
slope, which led to elevated IgY levels for a given bursal mass relative
to controls (R2 = 0.40, p = 0.026). Conversely, control males exhibited
a negative correlation between bursal mass and day 18 IgY, with fa-
drozole treatment tending to dampen the relationship (Fig. 5).
3.8. Testosterone-thymus relationship
Inclusion of brooder as a random effect did improve model fit
(σ2 < 0.0001 ± 0.00), so model selection was conducted using a LME
with this random effect. The 5 best-fit models retained log-testosterone,
Fig. 2. Plasma IgY antibody concentrations
for control and fadrozole-treated chicks. For
each boxplot, the middle line represents the
median, the bottom and top hinges re-
present the 25th and 75th percentiles, re-
spectively, and the whiskers extend to the
furthest outliers still within 1.5x the inter-
quartile range from the nearest hinge (25th
or 75th percentile).
Table 2
Predictors of size-corrected thymic mass estimated using model averaging for
the 3 best-fit models (all within 2 AICc of the top model).
Fixed effect Estimate SE z P
Treatment 0.001 0.0003 1.91 0.056
Sex −0.001 0.0003 1.73 0.083
Sex by treatment −0.001 0.0006 0.90 0.366
Fig. 3. Thymic mass (corrected for body mass) of
control and fadrozole-treated chicks. For each box-
plot, the middle line represents the median, the
bottom and top hinges represent the 25th and 75th
percentiles, respectively, and the whiskers extend to
the furthest outliers still within 1.5x the interquartile
range from the nearest hinge (25th or 75th percen-
tile).
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sex, treatment, a sex by treatment interaction effect, and a testosterone
by treatment interaction effect (Table 4). Model averaging indicated
that the interaction of log-testosterone by treatment and sex by treat-
ment were both marginally significant. The majority of females had
undetectable testosterone levels at day 18, precluding analysis of the
relationship between testosterone and thymic mass. In control males,
there was a negative relationship between plasma testosterone and size-
corrected thymic mass. In contrast, fadrozole-treated males exhibited a
positive relationship between plasma testosterone and size-corrected
thymic mass (Fig. 6).
3.9. Response to PHA
The inclusion of brooder as a random effect (σ2 = 0.00 ± 0.00) did
not improve model fit, so model selection was conducted with a GLM.
The null model was the best-fit model, but 3 other models were simi-
larly well-fit to the data. These 3 models retained sex and body mass in
various combinations; treatment was not included in any of the best-fit
models. Model averaging across the 4 top models did not reveal any
significant effects (all p > 0.14). Thus, treatment with fadrozole did
not influence the wing-web swelling response to injection with PHA.
Fig. 4. Plasma testosterone levels of control and fa-
drozole-treated chicks at day 3 and day 18 post-
hatch. Only individuals with detectable testosterone
levels are shown, though relative levels by sex and
treatment are unchanged if undetectable samples are
included. For each boxplot, the middle line re-
presents the median, the bottom and top hinges re-
present the 25th and 75th percentiles, respectively,
and the whiskers extend to the furthest outliers still
within 1.5x the interquartile range from the nearest
hinge (25th or 75th percentile).
Table 3
Predictors of day 18 IgY concentrations measured estimated using model
averaging for the 3 best-fit models (all within 2 AICc of the top model).
Fixed effect Estimate SE z P
Treatment −0.355 0.178 1.95 0.051
Sex 0.614 0.182 3.30 < 0.001
Bursa mass 36.17 25.66 1.38 0.168
Bursa by sex −104.5 30.83 3.32 < 0.001
Bursa by treatment 67.14 29.58 2.22 0.027
Sex by treatment −0.081 0.050 1.59 0.112
Fig. 5. Relationship between bursal mass and day 18 IgY levels by treatment for females (left) and males (right).
Table 4
Predictors of size-corrected thymic mass estimated using model averaging for
the 5 best-fit models (all within 2 AICc of the top model).
Fixed effect Estimate SE z P
Treatment 0.001 0.0004 1.40 0.161
Sex −0.001 0.0006 1.62 0.105
Testosterone 0.0003 0.0004 0.79 0.428
Testosterone by treatment 0.001 0.0006 2.03 0.043
Sex by treatment −0.002 0.0009 1.99 0.047




We show for the first time that prenatal inhibition of estrogen
production alters aspects of post-natal immunity in birds. Furthermore,
because estrogen synthesis was inhibited transiently during embryonic
development, the differences observed in chicks suggest that even
temporary changes in embryonic estrogen production can cause per-
sistent changes in aspects of immune physiology, indicating an orga-
nizational role for estrogens on the avian immune system. Aromatase
inhibition resulted in long-term changes to several immune measures
but did not alter plasma testosterone levels in postnatal animals.
Aromatase inhibition reduced Day 3 circulating IgY levels, increased
day 18 thymic mass, and increased day 18 IgY levels for a given bursal
mass in females. While thymic mass in control males was negatively
correlated with plasma testosterone titers, as expected (Mase and Oishi,
1991), the opposite was true of fadrozole-treated birds, with higher
plasma testosterone titers being associated with larger thymuses. Be-
cause E2, but not testosterone, levels were significantly altered during
the window of fadrozole activity, our results implicate E2 deprivation as
the likely agent of observed immune changes, and contribute to a
growing body of literature suggesting that developmental estrogens
may be as important as androgens in shaping the avian immune system
(Ahmed, 2000; Roberts et al., 2004; Owen-Ashley et al., 2004; Al-Afaleq
and Homeida, 1998).
4.2. Fadrozole activity validation
Fadrozole treatment on day 13 pre-hatch significantly decreased E2
in females on day 15 of incubation, with treated chicks exhibiting mean
plasma levels of about half their control counterparts (Fig. 1B). Fur-
thermore, treatment did not influence plasma testosterone levels at the
same time point, likely due to the overall higher levels of endogenous
testosterone relative to E2 (Fig. 1A). As this developmental window
represents a critical period for steroid hormone-mediated immune de-
velopment, and because testosterone levels were unaffected by treat-
ment, transient in ovo E2 deprivation is implicated as the likely causal
factor for immune effects observed at later time points in females.
For males, embryonic day 15 testosterone and E2 levels were un-
affected by fadrozole exposure (Figs. 2 and 3). It is unclear what sex-
specific factors account for the markedly different response to ar-
omatase inhibition at the time of measurement, with disparate fa-
drozole clearance profiles or differences in endogenous aromatase ex-
pression among the potential causes. Furthermore, because much of
endogenous aromatase activity is highly localized within target tissues,
circulating E2 concentrations may not always reflect site-specific E2
activity levels. There is some evidence to support this: in a 2013 study
of song acquisition in male songbirds in response to continuous ex-
posure to the aromatase inhibitor 1,4,6-androstatriene-3,17-dione
(ATD) via cranial implant, Bailey et al. documented a significant de-
crease in E2 within the hippocampus, but not in plasma levels (Bailey
et al., 2013). Thus, while a change in circulating E2 levels provides
strong evidence for efficacious treatment, the absence of such change
does not imply a lack of treatment effect, as the ATD-treated birds in
Bailey's study exhibited striking changes to behavior and physiology,
despite plasma E2 levels remaining unchanged. However, as we are
unable to conclusively demonstrate a reduction in E2 exposure for
males in this cohort, more caution must be applied in the interpretation
of post-hatch results in male birds.
4.3. Endogenous IgY
Fadrozole exposure tended to increase day 18 IgY levels for a given
bursal mass in females (Fig. 5). This relationship suggests that estreo-
gens inhibit bursal IgY production and supports hypothesis one which
states that downregulation of certain immune traits by testosterone is
mediated by aromatization of androgens. Because maternal IgY levels
become undetectable by day 14 post-hatch, day 18 IgY is entirely en-
dogenous (Hamal et al., 2006). The fact that the effect of fadrozole on
IgY levels varied from day 3 to day 18 also provides evidence that es-
trogens have different effects on different mechanisms within the im-
mune system. In this case, estrogens may promote uptake of maternal
IgY, perhaps via the FcRY receptor expression (see section 4.5) but
inhibit endogenous IgY production after hatching (Hamal et al., 2006;
Kondo et al., 2004).
4.4. Maternal IgY: Day 3 Post-Hatch
In ovo fadrozole exposure caused a reduction in Day 3 post-hatch
plasma IgY concentration, supporting hypothesis three which asserts
that aromatization induces a transition from downregulation to upre-
gulation of certain immune measures (Fig. 2). As IgY is not synthesized
endogenously until post-hatch day 6 in chickens, the IgY titers observed
at day 3 represent maternal antibodies that have been retained in the
developing chick (Hamal et al., 2006); thus these results are consistent
with the finding of Barua et al. that administration of E2 to hens results
in an increase in IgY deposition into their eggs (Barua et al., 2000).
Maternal IgY is transferred from the yolk to the embryo via a selective
receptor (FcRY) embedded within the yolk membrane (Tesar et al.,
2008). The observed decrease in IgY levels in response to develop-
mental aromatase inhibition can therefore be explained by either a
change in uptake (mediated either directly via alteration of FcRY ex-
pression or activity, or indirectly through some other means) or by
upregulation of IgY catabolism or excretion. We are not able to dis-
tinguish between these possibilities in this study, but to our knowledge,
this is the first study to demonstrate that inhibition of aromatase alters
uptake or retention of maternal IgY antibody. If expression or activity of
receptors for maternal antibodies can be directly influenced by hor-
mone exposure during prenatal development, it suggests a potential
interaction among different maternal effects (endocrine versus im-
mune). Variation in IgY uptake could have far-reaching effects on the
immune system because maternal IgY provides the basis of acquired
immunity until well after hatching (Hamal et al., 2006). Thus variation
in IgY uptake could introduce variation in the maturing immune system
and in susceptibility to early infection.
4.5. Thymic mass
Fadrozole exposure tended to increase body mass-corrected thymic
mass of 18 day old chicks in females (by about 15%; Fig. 3), suggesting
that endogenous estrogens inhibit thymic growth for a given body size
and therefore supporting hypothesis one which states that down-
regulation of certain immune traits by testosterone is mediated by
Fig. 6. Relationship between day 18 plasma testosterone levels and day 18
thymic mass for males by treatment.
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aromatization to E2. Our results corroborate previous studies in mam-
mals showing that the inhibitory actions of testosterone on thymic
growth are mediated in part by conversion to E2 (Greenstein et al.,
1988), and studies in amphibians showing that E2 treatment induces
apoptosis of thymocytes (Quinde et al., 2014). It is difficult to decipher
the fitness implications of a difference in thymic mass, because the size
of the thymus does not always correspond with T cell populations
(Hasselbalch et al., 1997). However, a change in thymic mass in re-
sponse to inhibition of pre-natal estrogen production represents a po-
tentially important alteration in immunological state.
4.6. PHA challenge
Fadrozole exposure had no effect on response to PHA. The PHA
response challenge has long been used as proxy for T cell mediated
immunity, and has become one of the most widely used ecoimmuno-
logical assays due to its simplicity and cost efficiency (Martin et al.,
2006). However, the mechanics of PHA-induced inflammation generate
a complex relationship between T cell activity and the PHA response.
While PHA does indeed induce T lymphocyte proliferation, the down-
stream inflammatory response involves a host of other cells as well as
regulatory factors, and it is ultimately macrophages, heterophils, and
basophils that are the direct agents of swelling (Stadecker et al., 1977;
McCorkle et al., 1980; Tella et al., 2008). For this reason, it has been
suggested that the PHA challenge assay be considered a “multifaceted
index of cutaneous immune activity”more so than a direct measure of T
cell mediated immunocompetence (Martin et al., 2006).
4.7. Plasma testosterone
The lack of differences among treatments in day 3 and day 18 chick
plasma testosterone levels (Fig. 4) suggests that the changes observed
were mediated by organizational effects allowing for long-term altera-
tion of physiology despite transient exposure to fadrozole (testosterone
should be elevated in fadrozole-treated chicks if it were still inhibiting
aromatase activity at those ages) (Sechman et al., 2003). Furthermore,
the lack of change in testosterone observed in ovo in response to
treatment, in contrast to the concomitant decrease in E2 in female
embryos, implicate E2 as the probable agent of immunomodulation
documented here. This assertion is bolstered by the literature, with a
wealth of studies showing that manipulation of in ovo testosterone ex-
posure in chickens produces inhibition of immune function (Glick,
1961, 1956; Hirota et al., 1976; Hillgarth and Wingfield, 1997; Navara
and Mendonca, 2008; Norton and Wira, 1977). Thus even if fadrozole
treatment had elevated testosterone in developing chicks, it would be
unlikely that the measures of immune function that were elevated in the
present study were driven directly by testosterone changes. In addition,
studies in rats provide precedent for some of our results.
In one experiment, aging and young adult rats were orchidecto-
mized and surgically implanted with testosterone or testosterone and
the aromatase inhibitor 1,4,6-androstatriene-3,17-dione (ATD). The
thymus naturally degenerates with age in rats, and the effect was ac-
celerated in the testosterone only treatment. However, the testos-
terone + aromatase inhibitor treatment caused a restoration of the
thymus, and even enlarged the gland in young intact rats, indicating
that testosterone-dependent thymic degeneration is contingent on ar-
omatization (Greenstein et al., 1992). Thus, our results, in conjunction
with previous studies, strongly implicate aromatization as a pathway
through which prenatal exposure to testosterone modulates immunity.
If this is the case, then our current understanding of testosterone’s role
in the development of avian immunity is incomplete. Manipulation of
testosterone either during development or in adulthood is a standard
method for studying the role of androgens, yet without accounting for
aromatization, it is impossible to distinguish between the effects of
testosterone and those of one of its active metabolites, E2.
4.8. Conclusion
We demonstrate that developmental aromatase inhibition alters
measures of immune activity in chickens. Combined with the long-
standing observations that exposure to testosterone generally results in
suppression of immune metrics, and that estrogens are strongly im-
munomodulatory, our results suggest that aromatization plays a crucial
role in the testosterone-mediated immunomodulation observed in de-
veloping birds, and that its role is immune metric-specific.
Experimental ablation alone is not sufficient to fully elucidate a
hormone’s role in a physiological process (Zera et al., 2007), and a more
integrative investigation, including ablation and replacement experi-
ments, manipulation with non-aromatizable androgens like dihy-
drotestosterone (DHT), molecular studies of estrogen receptors, and
fitness studies, will be needed to disentangle the relative contribution of
estrogens to the development of immune function in birds, and to un-
derstand the mechanisms by which variation in yolk testosterone
(whether endogenous or experimentally generated) may induce trade-
offs between the immune system and other aspects of phenotype.
However, the present study provides valuable groundwork towards this
end. Considering the paucity of data regarding estrogen-mediated im-
munomodulation in the context of physiological and behavioral ecology
relative to its precursor, testosterone, future investigations into endo-
crine-immune interactions may benefit from increased investigation
into the potential role of aromatization.
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